Tislelizumab Combined With Anlotinib and Chemotherapy (XELOX) in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (TALENT)

NCT04963088 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

65

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: BGB-A317
DRUG: Anlotinib
DRUG: Oxaliplatin
DRUG: Capecitabine

Sponsor

The First Affiliated Hospital with Nanjing Medical University